期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米合成路线图解 被引量：9

Graphical Synthetic Routes of Bortezomib
原文传递
导出
摘要 硼替佐米（bortezomib,1）,化学名为[（1R）-3-甲基-1-[[（2S）-1-氧代-3-苯基-2-[（吡嗪甲酰）-氨基]丙基]氨基]丁基]硼酸,商品名万珂（Velcade）,是由美国Millennium公司研发的蛋白酶体抑制剂,2003年经FDA批准上市,临床用于治疗多发性骨髓瘤,目前也已批准用于治疗复发难治性套细胞淋巴瘤。
作者 李忠 毛化 钟静芬
机构地区 中国医药工业研究总院上海医药工业研究院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2012年第5期393-395,共3页 Chinese Journal of Pharmaceuticals
关键词 合成路线图解 硼酸 MILLENNIUM 蛋白酶体抑制剂 多发性骨髓瘤 批准上市 化学名 商品名
分类号 R979.12 [医药卫生—药品]
  • 相关文献

参考文献11

  • 1姚淑娟,章萍,齐军元.硼替佐米联合沙利度胺治疗复发、难治性多发性骨髓瘤的疗效与安全性观察[J].药物不良反应杂志,2011,13(5):283-286. 被引量：6
  • 2谭振清,罗自勉,周新伏,尹亚飞,石煌,朱凯波,雷晓宇.硼替佐米联合化疗与常规化疗方案治疗多发性骨髓瘤的临床比较[J].临床医学,2012,32(3):1-4. 被引量：6
  • 3Furniss BS,Hannaford AJ,Smith PWG,et al.Vogel′s Textbook Practical Organic Chemistry[M].5th ed,Pearson:Harlow,1989:530-531.
  • 4Noller CR,Dinsmore R.Isobutyl bromide[J].Org Synth,1933,13:20-22.
  • 5Caldwell CG,Rupprecht KM,Bondy SS,et al.Synthesis of the lipophilic side chain of the cyclic hexadepsipeptide antibiotic L-156,602[J].J Org Chem,1990,55(8):2355-2361.
  • 6Pickersgill IF,Bishop J,Koellner C,et al.Synthesis of boronic ester and acid compounds:WO,2005097809[P].2005-10-20.(CA2005,143:387386)
  • 7Li YX,Plesescu M,Sheehan P.Synthesis of four isotopically labeled Forms fo A proteasome inhibitor,bortezomib[J].J Labelled Compd Radiopharm,2007,50(5-6):402-406.
  • 8Beenen MA,An C,Ellman JA.Asymmetric copper-catalyzed synthesis of-amino boronate esters from N-tert-butanesulfinyl aldimines[J].J Am Chem Soc,2008,130(22):6910-6911.
  • 9孙江涛,孔立.一种硼替佐米的合成方法:中国,101812026[P].2010-08-25.(CA2010,153:383296)
  • 10Venkata PR,Madinaguda MN,Hyderabad M,et al.Bortezomib and process for producing same:WO,2009036281[P].2009-03-19.(CA2009,150:330133)

二级参考文献22

  • 1Browman GP, Belch A, Skillings J, et al. Modified ad- ria-mycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study [ J]. Br J Haematol, 1992, 82 (3) :555-559.
  • 2Jagannath S, Durie BGM, Wolf J, et al. Bortezomib the- rapy alone and in combination with dexamethasone for pre- viously untreated symptomatic multiple myeloma [ J ]. Br J Haematol, 2005,129 (6) :776-783.
  • 3Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 200d[J]. CA-Cancer J Clin, 2004,54(1) :8-29.
  • 4Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for mul- tiple myeloma [ J]. N Engl J Med, 2003, 348: 1875- 1883.
  • 5Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma [ J]. Clin Cancer Res, 2004, 10:3954-3964.
  • 6Ciolli S, Leoni F, Gigli F, et al. Low dose velcade, tha- lidomide and dexamethasone (LD-VTD) : an effective re- gimen for relapsed and refractory multiple patients [ J ]. Leukemia Lymphoma, 2006, 47 ( 1 ) : 171-173.
  • 7Huang,YW, Hamilton A, Arnuk OJ, et al. Current drug therapy for Multiple Myeloma [J]. Drugs, 1999, 57(4) : 485 -506.
  • 8BladeJ, Samson D, Reece D, et al. Criteria for evalua ting disease response and progression in patients with mul- tiple myeloma treated by high-dose therapy and haemopoi etic stem cell transplantation [ J]. Br J Haemotol, 1998, 102(5):1115-1123.
  • 9National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) ~ DB/OL]. (2006-08- 09) [ 2011-07-20 ]. http ://ctep. cancer, gov/protocolDe- velopment/electronic_applications/docs/ctcaev3, pdf.
  • 10Durie BGM, Salmon SE. A clinical staging system formultiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treat- ment, and survival [J]. Cancer, 1975, 36(3):842-854.

共引文献11

同被引文献56

  • 1孙江涛,孔立.一种硼替佐米的合成方法:中国,101812026[P].2010-08-25.(CA2010,153:383296)
  • 2Li YX, Plesescu M, Sheehan P. Synthesis of four iso- topically labeled forms fo a proteasome inhibitor, borte- zomib[J]. J Labelled Compd Radiopharm, 2007, 50(5- 6): 402-6.
  • 3Zhu YQ, Zhao X, Zhu XR, et al. Design, synthesis, biological evaluation, and structure-activity relationship (sar) discussion of dipeptidyl boronate proteasome in- hibitors, Part I : Comprehensive understanding of the SAR of r-amino acid boronates[J]. J Med Chem, 2009, 52(14): 4192-9.
  • 4Piekersgill IF, Bishop J, Koellner C, et al. Synthesis of boronic ester and acid compounds: WO2005097809[P]. 2005-10-20. (CA 2005, 143: 387386).
  • 5Beenen MA, An C, Ellman JA. Asymmetric coppercat- alyzed synthesis of c-amino boronate esters from N- tertbutanesulfinyl aldimines [J]. J Am Chem Soc, 2008, 130(22): 6910-1.
  • 6Venkata PR, Madinaguda MN, Hyderabad M, et al. Bortezomib and process for producing same: WO2009036281 [P]. 2009-03-19. (CA 2009, 150: 330133).
  • 7Ivanov AS, Zhalnina AA, Shishkov SV. A convergent approach to synthesis of vortezomib: the use of TBTU suppresses racemization in the fragment condensation[J]. Tetrahedron, 2009, 65(34): 7105-8.
  • 8国家药典委员会.中华人民共和国药典:二部[S].2010年版.北京:中国医药科技出版社,2010:777-778.
  • 9Yerlikaya A,Okur E,Baykal AT,et al.A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line[J].J Proteomics,2014,3 919(14):315.
  • 10Adams J,Palombella V J,Sausville E A,et al.Proteasome inhibitors:a novel class of potent and effective antitumor agents[J].Cancer Research,1999,59(11):2615-2622.

引证文献9

二级引证文献17

中国医药工业杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部